Reported Earlier, Zai Lab's TIVDAK Receives China NMPA Approval Based On Phase 3 innovaTV 301 Trial Demonstrating Statistically Significant Overall Survival Benefit

Benzinga Newsdesk www.benzinga.com Positive 95.6%

Neg 0% Neu 0% Pos 95.6%

Comments

No comments yet. Be the first!